key: cord-0273209-wh5s3ks4
authors: Stewart, Alexander; Sinclair, Emma; Ng, Joseph; O’Hare, Joselli Silvia; Page, Audrey; Serangeli, Ilaria; Margreitter, Christian; Kasar, Nora; Longman, Katherine; Frampas, Cecile; Costa, Catia; Lewis, Holly; Wu, Bryan; Kipling, David; Openshaw, Peter; Chu, Christopher; Baillie, J Kenneth; Scott, Janet T; Semple, Malcolm G; Bailey, Melanie; Fraternali, Franca; Dunn-Walters, Deborah
title: Pandemic, epidemic, endemic: B cell repertoire analysis reveals unique anti-viral responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus
date: 2021-08-19
journal: bioRxiv
DOI: 10.1101/2021.08.19.456951
sha: 2994191f476c5a6119d145a68e253c9191323354
doc_id: 273209
cord_uid: wh5s3ks4

Immunoglobulin gene heterogeneity reflects the diversity and focus of the humoral immune response towards different infections, enabling inference of B cell development processes. Detailed compositional and lineage analysis of long read IGH repertoire sequencing, combining examples of pandemic, epidemic and endemic viral infections with control and vaccination samples, demonstrates general responses including increased use of IGHV4-39 in both EBOV and COVID-19 infection cohorts. We also show unique characteristics absent in RSV infection or yellow fever vaccine samples: EBOV survivors show unprecedented high levels of class switching events while COVID-19 repertoires from acute disease appear underdeveloped. Despite the high levels of clonal expansion in COVID-19 IgG1 repertoires there is a striking lack of evidence of germinal centre mutation and selection. Given the differences in COVID-19 morbidity and mortality with age, it is also pertinent that we find significant differences in repertoire characteristics between young and old patients. Our data supports the hypothesis that a primary viral challenge can result in a strong but immature humoral response where failures in selection of the repertoire risks off-target effects.

The emergence of SARS-CoV-2 in 2019, the ensuing pandemic and evolution of novel variants 43 continues to make COVID-19 a matter of global public health significance. The recent SARS, MERS, 44 Zika and Ebola outbreaks have also highlighted a need to better understand how the human immune 45 system responds to novel infections, develop better treatments and control their emergence and 46 spread. Initial reports from the COVID19 pandemic, relying heavily on serum antibody titres, saw 47 rapid declines in SARS-CoV-2 specific antibodies 1 that raised concerns over the nature and duration 48 of B cell memory. While total antibody titres decrease the persistent presence of SARS-CoV-2-49 specific memory responses some months after infection mitigates these concerns 2,3 . 50 Immunoglobulins (Ig), both as secreted antibodies and as B Cell Receptors (BCRs), mediate immunity 51 against multiple pathogens through their vast variability in antigen binding. This variability is 52 produced by V-D-J recombination 4 , where V, D and J genes are recombined from a pool of diverse 53

genes. B cells with Ig genes encoding disease-specific antibodies are expanded upon challenge, 54 causing a skewing of the repertoire towards greater use of antigen-specific genes associated with 55 the challenge in question. Furthermore, the imprecise joining of gene segments, together with the 56 action of terminal deoxynucleotidyl transferase (TdT) creates a highly diverse complementarity 57 determining region (CDR)3 region, which is important for antigen binding, and can be used to 58

identify "clones" of B cells within a repertoire. These clonal assignments allow us to track lineages 59

and follow the progress of the post-activation diversification events of somatic hypermutation (SHM) 60 and class switching (CSR) as the B cell response develops. Thus, repertoire analyses can help to 61 characterise changes in the memory/effector B cell compartments and identify individual genes of 62 interest for possible antibody therapeutics. 63

Both SHM and CSR are mediated by the enzyme Activation Induced cytidine Deaminase (AID) and 64 have traditionally been associated with germinal centre events in secondary lymphoid tissue, 65

involving T cell help 5-7 . There is, however, also evidence that CSR may occur outside the germinal 66 centre environment 8-11 and may not require direct T cell help. The ability of a B cell to mount a 67 directed effector response prior to the formation of a germinal centre allows a more rapid immune 68 response but with lower affinity. 69

Immune responses are often impaired in older people, which has been of particular concern in 70 COVID-19 patients. The older immune system has shown reduced responses to vaccination, 71

frequently with higher numbers of autoreactive antibodies and inflammatory cytokines 12-14 . In B cells 72

we, and others, have shown that particular subsets of B cells are altered with age: IgM memory cells 73

(CD19+CD27+IgD+) are decreased in older people while the Double Negative (CD19+CD27-IgD-) are 74

increased 15, 16 . Since IgM memory cells are often associated with a T-independent response, the 75 decrease in IgM memory in older people could have severe consequences in infections where a rapid 76 extrafollicular response is required 17,18 . It has also been shown that the B cell repertoire is skewed 77 towards sequences with longer more hydrophobic CDR3 regions as we age 16, 19 . As an immune 78 response can result in a shift towards lower, less hydrophobic CDR3 regions 14,20 , and higher 79 hydrophobicity has previously been correlated with increased polyspecificity 21-23 , the older immune 80

repertoire seems to be disadvantaged in this respect. 81

In this study we took a long-read repertoire amplification approach that allowed us to track the V-D- Physicochemical properties were calculated using the R Peptides package 28 . 140

Analysis of clonal diversity 141 We sought for methods to qualitatively (visualising clone size distribution) and quantitatively 142 compare clonal diversity (calculating metrics which summarise clonal diversity). We first noted, as 143 one would expect, that sequencing depth (i.e., number of sequences sampled per repertoire) was a 144 strong predictor of the number of clones (Supplementary Figure S1 ). For all repertoires considered 145

here, a wide range of sequencing depth was observed (number of sequences range from 836 to 146 105,323, median = 12,040). We therefore adopted the following procedure in this analysis: first, to 147 quantify the extent of clonal diversity we used the Gini coefficient which measures the evenness in 148 the distribution of clone size across clones; application of this metric to quantify BCR clonal diversity 149 has been well documented 29-31 . For a given repertoire, clones were ordered by their clone sizes, and 150 the cumulative distributions of clone sizes (in terms of percentage of sequences in repertoire) and its 151 percentile distribution were compared for evenness. As such, the resulting metric was independent 152 from the absolute numbers of sequences and clones, thereby allowing fair comparison across 153

repertoire of different sequencing depths. As Gini coefficient is an indicator of evenness, we took (1 154

-Gini coefficient) as the metric of clonal diversity. To qualitatively compare clonal diversity, we 155 generated visualisation using the following procedure to minimise the impact of sequencing depth 156 differences: we first sampled 12,000 sequences (≈ median sequencing depth; see above) from each 157

repertoire; for repertoires with less than 12,000 unique observations, this number of sequences 158

were sampled with replacement. We then sampled up to 100 clones with probability scaled by clone 159 sizes to generate bubble plots where each bubble represents a clone and bubble sizes are scaled 160 with clone sizes. Genotypic features like V gene usage can be represented as colours. Such plots 161

were included in Figure 2c . 162

Lineage trees were reconstructed using the maximum parsimony method implemented in the 164 dnapars executable in the phylip package 32 . All clones with at least 3 sequences were considered; 165

IMGT-gapped, V-gene nucleotide sequences of all observations in the clone together with the 166 annotated germline V-gene sequence (included to root the tree) were included as input to dnapars. 167

Functionalities implemented in the alakazam R package 33 were used to call dnapars and reformat the 168 output into text-based tree files (newick format) and directed graphs (igraph objects manipulated in 169 R). The directed graphs were further parsed using functions in alakazam and igraph to obtain, for 170 each observed sequence in the given clone, its distance D from the given germline gene g (denoted 171

here as ), as estimated by the dnapars-reconstructed lineage tree: the closer this distance is to 0, 172 the closer the sequence is to germline and therefore a lower mutational level. 173

We sought to summarise, for a given clone, the distribution of ; this distribution would indicate 174 the overall mutational level of sequences within the clone (summarised using conventional statistics 175 like the median of ) and the evenness of mutational level (i.e. whether the clone consists of 176 expansion of sequences with a similar mutational level, or it comprises sequences with a wide range 177 of mutational levels). This can be visualised as a heatmap (clones [vertical axis] versus [horizontal 178 axis], with colours scaling with density of the distribution; see Figure 5b ), or as a curve (clones 179

[vertical axis] versus the median of [horizontal axis], See Figure 5c ). The curve representation 180 allows calculation of area-under-curve (AUC) as a metric which we termed "Germline Likeness", to 181 quantify mutational levels across clones. This is similar to quantifying sequence similarity to 182 germline, except that here Germline Likeness quantifies the tendency to which all clones from the 183 BCR repertoire of a given individual have high similarity to the germline (and therefore lower 184 mutational levels). 185

Detecting class-switch recombination events from lineage trees 186

Since the lineage trees were constructed using only V-gene sequences (see above), in theory 187 antibody sequences of different subclasses could be ordered in the tree in a way that imply class-188 switch recombination (CSR) events which are mechanistically impossible. We therefore pruned the 189 dnapars-reconstructed tree to remove edges which imply CSR events that violates the physical order 190

of Figure S6) . To investigate whether clusters shared 223 across disease conditions exist, convergent networks were also constructed considering CV, RSV and 224 EBOV repertoire and binder sequences altogether (Supplementary Figure S7) . Supplementary Table  225 S6 contains all convergent networks constructed, presented as list of pairwise sequences. 226 Large clone sizes can mask whole repertoire changes, so we analysed the frequency of gene use 275 after reducing the data to one representative sequence per clone. We found increased use of IGHV3-276 30 in IgM mutated sequences in CV19 patients (Figure 2e) , and also of IgM-mutated/IgA1/IgG1 in 277 CV19R, this was unique to CV19. An increase in use of IGHV4-39 was found in CV19 IgA1 sequences 278 and was also found increased across the board in EBOV and RSV-U samples (Figure 2e ). IGHV3-23 279 was found to be reduced in ongoing infection (likely an offset as a result of relative increases in 280 usage of other genes) but exceeded the healthy levels in CV19R and RSV-I. IGHV1-69, which has 281 previously been associated with viral infections 47,48 was increased in RSV-I but not EBOV or CV19. 282

The YF day 28 vaccine samples increased use of IGHV3-7 in IgM-mutated and IGHV1-2 in IgG1 only 283 (Supplementary Figure S4) . 284

Given the importance of CDRH3 in antibody recognition, and the contribution to CDRH3 from the 286 IGHD and IGHJ genes, we analysed these also. In CV19 samples there was a significant increase in 287 use of IGHD2-2, IGHD3-3 and IGHJ6 (Figure2e). These genes tend to be more hydrophobic (IGHJ6 288 being the exception) and all have among the longest amino acid lengths with only IGHD3-16 being 2 289 AA longer. This contribution can be seen in the overall CV19 repertoire which skews towards longer 290 amino acid sequences and increased hydrophobicity, indicative of early response as affinity 291 maturation causes shorter less hydrophobic CDRs (Supplementary Figure S5) . A clustering analysis of 292 peptide physicochemical properties of CDRH3 regions generally results in a difference between IgM 293 sequences and memory sequences (Figure 2f ), presumably reflecting biases in antigen selection 294 during post-challenge development. We can see that healthy and CV19 subclass sequences mostly 295 have similar CDRH3 properties to each other, however, in the case of CV19 IgG1 and IgG3 cluster 296 closer to IgM sequences from healthy and EBOV rather than healthy IgG1 and IgG3 sequences 297 implying a more 'naïve', unselected, repertoire. 298

To assess the functional importance of the skewed patterns of V, D and J gene usage in CV19 we 300 created networks connecting sequences observed in our CV19 and control repertoire data ( Figure  301 3a), using criteria previously employed in discovering 'convergent' antibody sequences shared 302 between patients 49 . By also including known SARS-CoV-2 binders we obtain clusters of CDR3 303 sequences found in both CV19 patients and healthy controls, some of which converge towards 304 known binders of SARS-CoV-2 proteins such as those targeting the receptor binding domain (RBD) of 305 the spike protein (Figure 3b ). Many of these large convergent clusters did not, however, include a 306 known binder in the network (Figure 3c) . Overall, convergent clusters use a diverse set of V genes, 307 but most of our larger convergent clusters contain IGHV3 or IGHV4 families and demonstrate 308

increased IGHJ6 usage as well as the more commonly used IGHJ4 (Figure 3c) . A comparison 309 exclusively of the known binders to date reveals distinct combinations of V and J gene preferences 310 (Figure 3d ). We do find clusters of sequences using IGHV3-53 and IGHV1-58 such as those used in 311

anti-RBD antibodies (e.g. Figure 3b ). We find that sequences from convergent clusters tend to be 312 found in larger clonal expansions than those without evidence of convergence (Figure 3e) , possibly 313

implying that specific clonal expansions in response to challenge are shared across patients. We 314 note that half of the larger clusters have substantial contributions from healthy control sequences, 315 so there may be some IGH genes, such as IGHV3-33/IGHJ5 found also in RSV-I and EBOV convergent 316 networks (Figure 3c, Supplementary Fig6a&b) , which have increased versatility such that they are 317 often seen in response to multiple different challenges. 318 Similar analyses of RSV and EBOV repertoires were limited by the paucity of information on antibody 319 binders, however it was notable that only RSV-I, and not RSV-U, showed evidence of convergence. 320

IGHV1-18 appears in a large cluster with a known RSV F-protein binder and although the large 321 IGHV3-23 cluster does not contain a known binder it forms part of the larger expansion of IGHV3-23 322 genes in mutated IgM genes from this cohort (Figure 2e, Supplementary Figure S6b) . 323

Age-related differences 324

The disparity in CV19 severity and mortality between age groups is striking, so we looked for age-325 related differences in our B cell repertoire data. The difference in IgA1/IgA2 ratio is less in older 326 people, not reaching significance. (Figure 4a ). On the other hand, the increase usage of IgG1 in CV19 327 and concomitant decrease in IgG2 are robust across age (Figure 4b ). Considering Ig gene usage, we 328 observe the intriguing case of IGHV3-30 which is only preferentially used by the over 60s during 329 infection ( Figure 4c ). Conversely, IGHV3-53, which appears relatively frequently in known binder 330 data in combination with IGHJ4/6 but did not appear in our total cohort analysis (Figure 2e ), is 331 significantly increased in the under 50s IgM-mutated partition (Figure 4c ). We also found that 332

IGHV4-39, IGHD2-2, IGHD3-3 and IGHJ6, which we find are expanded in CV19 across multiple B cell 333 partitions, only have significantly increased expression in the under 50s and not the over 60s IGHV4-334 34 appeared increased in both age groups. (Figure 4c ). 335

Beyond the scope of gene usage, our BCR repertoire data also enabled reconstruction of individual 337 BCR lineage trees to make inferences about the evolution of a particular clone. Using the annotated 338 germline V allele as the root of the tree, we estimate, for each sequence in the lineage, its distance 339 from the root (Figure 5a ); this distance being directly proportional to mutational level. We visualise 340 the distribution of this germline distance across all clonotypes observed in each given individual, and 341

observe that the repertoire is dominated by clonotypes with very low mutational levels for a subset 342 of CV19 patients, whilst the predominance of such clones is broadly absent in healthy controls 343 (Figure 5b, c) . Interestingly, in repertoires from convalescent individuals (both EBOV and CV19), we 344 instead observe dominance of clonotypes with higher mutational levels, although the pattern is less 345 striking than the CV19 patients during hospitalisation (Figure 5c ). These curves allow for 346 quantification of the Area Under the Curve (AUC), which constitutes a metric we term "Germline 347

Likeness": a higher Germline Likeness corresponds to a lower level of mutation across all clones 348 ( Figure 5d ); this is akin to quantifying sequence similarity to the germline, except that Germline 349

Likeness here quantifies such phenomenon for a given repertoire in general, rather than a specific 350 sequence. Using this metric we confirm that CV19 repertoires were dominated by clones that were 351 largely unmutated, while EBOV samples carried the greatest mutation rate (Figure 5e ). As might be 352 expected, with time to generate a germinal centre response, Germline Likeness in CV19 faded with 353 time (Figure 5f ), to the point where the CV19R repertoires have similar level of mutations compared 354

to the EBOV-convalescent and healthy control repertoires. Partitioning the analysis by isotype, RSV 355 and healthy controls demonstrate the expected trend where an increased level of mutations can be 356 found in both IgG and IgA compared to IgM (Figure 5g ). However, in CV19 only IgA showed a 357 significant change in Germline Likeness from IgM (Figure 5g) . 358

Our lineage trees were further analysed for CSR events: respecting the sequential order of CSR in the 360 genome, we identify CSR events where sequences of different antibody classes/subclasses are 361 directly connected in the lineage tree. This enables us to trace the timing of CSR events (distance 362 from the germline), the direction of class switching (e.g. from IgM to IgG1) and frequency of 363 observation. Many clones have evidence of CSR in CV19 and EBOV, even after correcting for clone 364 sizes (Figure 6a ). In particular, CV19 patients were more likely to switch early to IgG1 from IgM, with 365 little mutation (Figure 6b , c, d) and to IgA1 from either IgM or IgG1 later in the lineage with more 366 mutation (Figure 6b,d) . This agrees with the lack of CDRH3 "maturity" in IgG1 (Figure 2f ) and the 367 overall increased use of IgG1 and IgA1 seen in CV19 (Figure 2 a, b) . 368

The evidence of increased CSR in convalescent EBOV patients is striking and occurs across the board 369

with the exception of IgM switching to IgG1 (Figure 6d ). We noticed that although there is a similar 370 pattern of CSR preferences in White and West Africans individuals, the overall distance from 371 germline is longer before CSR occurs in West Africans (Figure 6b ). This may suggest that the ethnic 372 bias in existing immunoglobulin sequence databases has resulted in mis-assignment of germline 373

alleles. No CSR differences were seen in the RSV data. 374

We compared immunoglobulin gene sequences from pandemic (SARS-CoV-2), epidemic (Ebola) and 376 endemic (Respiratory Syncytial Virus) patients in order to discover features that might distinguish 377 newly emergent and endemic infections. for IGHD2-2, IGHD3-3 and IGHJ6 only in the young, with IGHJ6 occurring frequently in known binder 428 networks, given the importance of IGHD and IGHJ genes to the CDRH3 region it is striking that the 429 differences seen here are solely in the younger age group. 430

In comparison to our CV19 data our Ebola data paints an unusual picture where, even 2-3 months 431 post-recovery with viral negative PCR tests, there are abnormally high proportions of class switched 432 clones with little or no direction towards a particular sub-class. Given CSR is largely understudied, as 433 far as we can tell such high rates of class switching, particularly so long after recovery, is entirely 434 unique to this infection. Another unusual observation was that EBOV survivor's memory B cell 435 populations were more diverse than healthy controls suggesting stimulation with more diverse 436

antigens, or a less structured and directed immune response. A 'decay-stimulation-decay' pattern 437 resulting in the peak of antibody response being some 200 days after infection has previously been 438 reported 67 and cytokine storms during infection may also be contributing to this phenomenon 68,69 . 439

It was not possible to collect blood samples from unrecovered patients, so we do not know if these 440 observations were a requirement of patient recovery or a phenomenon unique to Ebola infection in 441

general. 442

By comparing examples of pandemic, epidemic and endemic viral disease responses our results 443

show that while aspects of B cell responses are unique to particular infections, the human 444 immunoglobulin gene repertoire can show similarities of response across two very different 445

diseases. There are many questions to be answered about the balance of beneficial versus 446 bystander responses in acute inflammatory diseases, where the initial class switched responses 447 seem to be immature (CV19) and possibly unregulated (EBOV infection). Coupled with the finding of 448 genes such as IGHV4-39 appearing in two completely different diseases, these data add weight to 449 the hypotheses that an emergency humoral immune response to primary challenge can bypass 450 normal stringent regulation and thus allow the production of autoimmune antibodies. 451 

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 486 infection

Durability of Immunity to SARS-CoV-2 and 488 Other Respiratory Viruses

Humoral Immune Response to SARS-CoV-2 in Iceland

V(D)J recombination, somatic hypermutation and class switch 492 recombination of immunoglobulins: mechanism and regulation

Immunoglobulin class-switch DNA 495 recombination: Induction, targeting and beyond

Mechanism and regulation of class switch 498 recombination

Processive AID-catalysed cytosine 500 deamination on single-stranded DNA simulates somatic hypermutation

Class-Switch Recombination Occurs Infrequently in Germinal Centers

Visualization of the genesis and fate of isotype-switched B cells during a 505 primary immune response

Immunoglobulin switch transcript production in vivo related to the site and time of antigen-508 specific B cell activation

Single-cell analysis of human B cell maturation predicts how antibody class 510 switching shapes selection dynamics

Age-Related Changes in B Cells 512 Relevant to Vaccine Responses

The effect of aging of the immune system on vaccination responses. Human 514 Vaccines and Immunotherapeutics

Vaccination-induced changes in human B-cell repertoire and 516 pneumococcal IgM and IgA antibody at different ages

A double-negative (IgD-CD27-) B cell population is increased in the 518 peripheral blood of elderly people

High-throughput immunoglobulin repertoire analysis distinguishes between 520 human IgM memory and switched memory B-cell populations

A germinal center-independent pathway generates 522 unswitched memory B cells early in the primary response

The continuing story of T-cell independent 524 antibodies

Age-related changes in human peripheral 526 blood IGH repertoire following vaccination

Significant differences in physicochemical properties of human 528 immunoglobulin kappa and lambda CDR3 regions

Immunoglobulin gene analysis as a 530 tool for investigating human immune responses

Aggregation-resistant 533 domain antibodies engineered with charged mutations near the edges of the 534 complementarity-determining regions

Promiscuous antibodies characterised by their physico-chemical properties: 536 From sequence to structure and back

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a 538 Serological Assay, Antigen Production, and Test Setup

Detection, characterization, and enrollment of donors of Ebola 541 convalescent plasma in Sierra Leone

Impaired antibody-mediated protection and defective iga b-cell memory in 543 experimental infection of adults with respiratory syncytial virus

Age-related aspects of human IgM+ B 546 cell heterogeneity

Peptides: A Package for Data Mining of 548

B cell receptor repertoire analysis in six immune-mediated diseases

Single-cell multi-omics analysis of the immune response in COVID-19

Network properties derived from deep sequencing of human 554 B-cell receptor repertoires delineate B-cell populations

PHYLIP -Phylogeny Inference Package (Version 3.2)

B cells populating the multiple sclerosis brain mature in the draining 558 cervical lymph nodes

SAbDab: the structural antibody database

Evolution of antibody immunity to SARS-CoV-2

Rapid isolation and profiling of a diverse panel of human monoclonal 563 antibodies targeting the SARS-CoV-2 spike protein

Convergent antibody responses to SARS-CoV-2 in convalescent 565 individuals

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing 567 Antibodies from COVID-19 Patients

Profiling B cell immunodominance after SARS-CoV-2 infection reveals 569 antibody evolution to non-neutralizing viral targets

Potent neutralizing antibodies from COVID-19 patients define multiple 571 targets of vulnerability

Broadly Reactive Anti-Respiratory Syncytial Virus G Antibodies from 573 Exposed Individuals Effectively Inhibit Infection of Primary Airway Epithelial Cells

Infants Infected with Respiratory Syncytial Virus Generate Potent 576 Neutralizing Antibodies that Lack Somatic Hypermutation

Rapid profiling of RSV antibody repertoires from the memory B cells of 578 naturally infected adult donors

Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection

BRepertoire: a user-friendly web server for analysing antibody repertoire 582 data

IgG subclasses and allotypes: From structure to 584 effector functions

VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-586

Mediated Effector Functions Against the Transmitted/Founder gp120

IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, 589 correlates with IGHV utilization shifts and varies by ethnicity

Human B Cell Clonal Expansion and Convergent Antibody Responses to 591 SARS-CoV-2

Establishing the prevalence of common tissue-specific autoantibodies following 593 severe acute respiratory syndrome coronavirus 2 infection

Autoantibodies against type I IFNs in patients with life-threatening COVID-596 19

Association between molecular lesions and specific B-cell receptor subsets in 598 chronic lymphocytic leukemia

Differences in the ease with 600 which mutant viruses escape from human monoclonal antibodies against the HA stem of 601 influenza A virus

Germline Ig Gene Repertoire HIV-1 Antibodies Is Not Restricted 603 by the Ability To Develop Broadly Neutralizing

Germline-encoded neutralization of a Staphylococcus aureus virulence 605 factor by the human antibody repertoire

Class switch recombination and hypermutation require activation-607 induced cytidine deaminase (AID), a potential RNA editing enzyme

Specific expression of activation-induced cytidine deaminase (AID), a 609 novel member of the RNA-editing deaminase family in germinal center B cells

BCR-signalling synergizes with TLR-signalling for induction of AID and 612 immunoglobulin class-switching through the non-canonical NF-κB pathway

Extrafollicular B cell responses correlate with neutralizing antibodies 615 and morbidity in COVID-19

IgG subclass distribution of antibodies to bacterial 617 and viral antigens

Longitudinal SARS-CoV-2 antibody study using the Easy Check

IgM/IgG TM lateral flow assay

Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for 621 assessing dynamics of antibody responses to SARS-CoV-2

Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in 623 a national COVID-19 seroprevalence survey

Evaluation of SARS-CoV-2 serology assays reveals a range of test 625 performance

Performance of six SARS-CoV-2 immunoassays in comparison with 627 microneutralisation

The ageing human B cell repertoire: a failure of selection?

Ebola virus antibody decay-stimulation in a high proportion of survivors. 631

Immunopathology of highly virulent pathogens: 633 Insights from Ebola virus

Phosphatidylserine's role in Ebola's inflammatory cytokine storm and 635 hemorrhagic consumptive coagulopathy and the therapeutic potential of annexin V

649 (a-b) Difference in sub-class use of IgA (A) and IgG (B) in viral disease and healthy BCR repertoires. (c) Clonal 650 expansion of sequences of relevant effector types (as revealed in A) plus unmutated and mutated IgM to 651 identify trends of V gene usage in viral infections. Each bubble sampled to a uniform depth (see Methods), 652 with size proportional to clone size, represents one clone colour-coded by V-family usage. (d) Quantification of 653 clonal expansion calculated using the Gini coefficient (see methods), revealed clonally expanded effector 654 populations (more monoclonal/less diverse

Dashed 656 line indicates the median diversity in the Healthy cohort. (e) Frequency of selected V-D-J gene usage in 657 different cohorts for all sequences and further subdivided by IgM-mutated, IgA1, IgG1. Bar charts depict gene 658 frequency usage in the Healthy cohort

Note that IgG1 and IgG3 sequences from CV19 cluster together with IgM

Statistical significance 663 in panels a, d and e was evaluated using one-way ANOVA and Dunnett post-hoc comparison against the 664

Healthy cohort: p-value indicated either with colour (panel c), bubble size (e) or the symbols under the 665 following scheme: *

Known binder networks were created using same V, J and CDR3 length with at least 85% amino acid 670 (AA) identity. (b) Convergent clusters from healthy and CV19 repertoire with known PDB structures. IGHV and 671 IGHJ use and the CDR3 AA sequence were noted. (c) Clusters containing at least 10 sequences were visualized, 672 with breakdown of repertoire origin (stacked bar plots), and the IGHV and IGHJ gene usage of each cluster 673 aligned beneath. The number of donors with sequences in each depicted clusters are shown as bar graphs 674 (bottom panel, c), broken down into subsets with age <50 (light grey) and >60 (dark grey). (d) All known 675 binders were analysed for similarity of IGHV/J gene use to specific SAR-CoV-2 antibody targets (d)

Age differences in V-D-J and isotype usage in CV19 repertoires

Statistical significance evaluated using two-way ANOVA 686 and Tukey's post-hoc test: *, p < 0.05; **

Figure 5. Mutational levels in BCR lineages

This allows ordering of sequences based on this distance from germline: depicted as a histogram 692 [(a) bottom right]. (b) Clones in the repertoire, for selected donors, were ordered (vertical axis) using median 693 distance from germline (horizontal axis), and the distribution of such distance for each clone was plotted with 694 heatmap colours being the percentage of sequences within the clone containing the a given level of mutation. 695 (c) Distance from germline distributions for every donor, split by condition, represented as curves. Dotted line 696 represents the theoretical expectation of mutational level. (d) From each of these curves (in c) the area under 697 the curve (AUC) was calculated giving a statistic of 'Germline Likeness', a higher AUC resembling more the 698 germline and a lower AUC indicating more mutations. (e) Comparison of Germline Likeness between 699 conditions: sample types with significant (p < 0.05) differences compared to Healthy (Wilcoxon rank-sum test) 700 are highlighted in red with the dotted line being the healthy median. (f) The Germline Likeness across 701 timepoints for CV19 patients with Healthy and Ebola data are reproduced here for comparison

708 (a) Lineage clones (see Figure 5) were assessed for prevalence of CSR events in terms of the proportion of 709 clones and plotted by clone size and split by condition. (b) Bubble plot depicting the frequency and distance-710 from-germline of CSR events, separated by the CSR start

Bubble sizes are proportional to 712 the frequency of CSR and colour is scaled by distance from germline at which CSR occurs, as estimated from 713 the reconstructed lineage trees. (c) Statistical comparison of the median distance from germline at which CSR 714 events occurred across sample types. Each donor was considered separately for every switch possibility

Statistical significance was evaluated using one-way ANOVA and Dunnett 717 post-hoc comparison against Healthy with p < 0.05 highlighted in red (c, d)

Young: 3/6 (50%) Older: 3/6 (50%)

Young: 3/6 (50%) Older: 3/6 (50%)

Young: 3/12 (50%) Unknown: 9/12 (50%)